Neumodx sars cov 2 assay

Nasopharyngeal samples were tested by RT-PCR using either the Cobas^® SARS-CoV-2 (Roche, Switzerland) on a Cobas^® 6800 system [11 (link)] or the NeuMoDx^® SARS-CoV-2 Assay (QIAgen, Germany) on a NeuMoDx^® 288 system [12 (link)]. Cycle threshold (Ct) values of the ORF1ab and N targets were used as a proxy for viral load for the Cobas and the NeuMoDx assay, respectively. All Ct values above 40 were considered negative for all tests, as recommended by the respective manufacturers. Screening for SARS-CoV-2 variants of concern (VOC) was performed using real-time specific RT-PCR SARS-CoV-2 Spike (i.e., deletion 69-70, E484K and N501Y mutations) (TIB Molbiol, Berlin, Germany).

NPS were collected by a health care professional and were placed directly onto a viral transport medium before transport to the laboratory. Fresh, self-collected saliva were transported to the laboratory without any viral transport media and were then diluted in phosphate-buffered saline (PBS) and lysis buffer before amplification (5 (link)).
Molecular detection was based on the RT-PCR amplification of at least two viral genome regions. The assays used by our laboratory during the study period were the Cobas SARS-CoV-2 assay (“ROC”, Roche Molecular Diagnostics, Mannheim, Germany), Alinity m SARS-CoV-2 assay (“ALI”, Abbott Molecular, Rungis, France), NeuMoDx SARS-CoV-2 assay (“NMDx”, Qiagen, Courtaboeuf, France), Xpert Xpress SARS-CoV-2 assay (“CPH”, Cepheid, Maurens-Scopont, France), and Simplexa COVID-19 Direct assay (“SPX”, DiaSorin, Antony, France).
Our laboratory information system collected results expressed as cycle threshold (Ct) values. For assays with multiple targets, the mean Ct value was calculated.

NPS were collected by a health care professional and were placed directly onto a viral transport medium before transport to the laboratory. Fresh, self-collected saliva were transported to the laboratory without any viral transport media and were then diluted in phosphate-buffered saline (PBS) and lysis buffer before amplification (5 (link)).
Molecular detection was based on the RT-PCR amplification of at least two viral genome regions. The assays used by our laboratory during the study period were the Cobas SARS-CoV-2 assay (“ROC”, Roche Molecular Diagnostics, Mannheim, Germany), Alinity m SARS-CoV-2 assay (“ALI”, Abbott Molecular, Rungis, France), NeuMoDx SARS-CoV-2 assay (“NMDx”, Qiagen, Courtaboeuf, France), Xpert Xpress SARS-CoV-2 assay (“CPH”, Cepheid, Maurens-Scopont, France), and Simplexa COVID-19 Direct assay (“SPX”, DiaSorin, Antony, France).
Our laboratory information system collected results expressed as cycle threshold (Ct) values. For assays with multiple targets, the mean Ct value was calculated.